{
    "root": "30891c38-5d64-7df7-e063-6394a90ae762",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atazanavir",
    "value": "20250317",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "MB5IUD6JUA"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "ATAZANAVIR SULFATE",
            "code": "4MT4VIE29P"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        }
    ],
    "indications": "Atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. \n    Limitations of Use: \n    • Atazanavir are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus\n \n  [see Use in Specific Populations (\n  \n   8.4)]\n \n  .  \n    • Use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions\n \n  [see Microbiology (\n  \n   12.4)]\n \n  .",
    "contraindications": "• Pretreatment testing: Renal laboratory testing should be performed in all patients prior to initiation of atazanavir capsules and continued during treatment with atazanavir capsules. Hepatic testing should be performed in patients with underlying liver disease prior to initiation of atazanavir capsules and continued during treatment with atazanavir capsules. ( 2.2 ) • Treatment-naive adults: Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food or atazanavir 400 mg once daily with food. ( 2.3 ) • Treatment-experienced adults: Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food. ( 2.3 ) • Pediatric patients: Atazanavir capsule dosage is based on body weight not to exceed the adult dose and must be taken with food. ( 2.4 ) • Pregnancy: Atazanavir capsules 300 mg with ritonavir 100 mg once daily with food, with dosing modifications for some concomitant medications. ( 2.6 ) • Dosing modifications: may be required for concomitant therapy ( 2.3 , 2.4 , 2.6 ), renal impairment ( 2.7 ), and hepatic impairment. ( 2.8 )",
    "warningsAndPrecautions": "Atazanavir Capsules 150 mgare off white to pale yellow colored granular powder filled in size \"1\" hard gelatin capsules with green opaque cap imprinted with \"H\" in black color and light green opaque body imprinted with \"A6\" in black color. \n    Bottles of 60 with child-resistant closure          NDC 31722-653-60 \n    Bottles of 1000 with child-resistant closure      NDC 31722-653-10 \n    Carton of 100 (10×10) unit-dose capsules       NDC 31722-653-31 \n    150 mg atazanavir equivalent to 170.854 mg atazanavir sulfate. \n  \n                     Atazanavir Capsules 200 mgare off white to pale yellow colored granular powder filled in size \"0\" hard gelatin capsules with green opaque cap imprinted with \"H\" in black color and light green opaque body imprinted with \"A7'' in black color. \n    Bottles of 60 with child-resistant closure          NDC 31722-654-60 \n    Bottles of 1000 with CT closure                       NDC 31722-654-10 \n    Carton of 100 (10×10) unit-dose capsules       NDC 31722-654-31 \n    200 mg atazanavir equivalent to 227.805 mg atazanavir sulfate. \n  \n                     Atazanavir Capsules 300 mgare off white to pale yellow colored granular powder filled in size \"00\" hard gelatin capsules with orange opaque cap imprinted with \"H\" in black color and green opaque body imprinted with \"A8\" in black color. \n    Bottles of 30 with child-resistant closure            NDC 31722-655-30 \n    Bottles of 500 with child-resistant closure          NDC 31722-655-05 \n    Carton of 100 (10×10) unit-dose capsules         NDC 31722-655-31 \n    300 mg atazanavir equivalent to 341.708 mg atazanavir sulfate. \n    Keep capsules in a tightly closed container. \n    Store atazanavir capsules at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Atazanavir capsules are contraindicated: \n    • in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens- Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules\n \n  [see Warnings and Precautions (\n  \n   5.2)]\n \n  . \n    • when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or life-threatening events (see Table 6). \n    • when coadministered with drugs that strong inducers of CYP3A due to the potential for loss of therapeutic effect and development of resistance. \n    Coadministration is contraindicated with, but not limited to, the following drugs listed in Table 6: \n  \n                     Table 6: Drugs Contraindicated with Atazanavir (Information in the table applies to atazanavir with or without ritonavir, unless otherwise indicated)\n                  \n                  \n                  \n                     \n                     \n                     \n                        \n                           \n                              Drug Class\n                              \n                           \n                           \n                              Drugs within class that are contraindicated with Atazanavir capsules\n                              \n                           \n                        \n                        \n                           Alpha 1-adrenoreceptor antagonist \n     \n                           \n                           Alfuzosin \n     \n                           \n                        \n                        \n                           Antiarrhythmics \n     \n                           \n                           Amiodarone (with ritonavir), quinidine (with ritonavir) \n     \n                           \n                        \n                        \n                            Anticonvulsants        \n                            Carbamazepine, phenobarbital, phenytoin\n                        \n                        \n                           Antimycobacterials \n     \n                           \n                           Rifampin \n     \n                           \n                        \n                        \n                           Antineoplastics \n     \n                           \n                           Apalutamide, encorafenib, irinotecan, ivosidenib \n     \n                           \n                        \n                        \n                           Antipsychotics \n     \n                           \n                           Lurasidone (with ritonavir), pimozide \n     \n                           \n                        \n                        \n                           Benzodiazepines \n     \n                           \n                           Orally administered midazolam\n    \n     a, triazolam \n     \n                           \n                        \n                        \n                           Ergot Derivatives \n     \n                           \n                           Dihydroergotamine, ergonovine, ergotamine,  methylergonovine \n     \n                           \n                        \n                        \n                           GI Motility Agent \n     \n                           \n                           Cisapride \n     \n                           \n                        \n                        \n                           Hepatitis C Direct-Acting Antivirals \n     \n                           \n                           Elbasvir/grazoprevir; glecaprevir/pibrentasvir \n     \n                           \n                        \n                        \n                           Herbal Products \n     \n                           \n                           St. John’s wort (\n    \n     Hypericum perforatum) \n     \n                           \n                        \n                        \n                           Lipid-Modifying Agents: \n     \n                           \n                           Lomitapide, lovastatin, simvastatin \n     \n                           \n                        \n                        \n                           Phosphodiesterase-5 (PDE-5) Inhibitor \n     \n                           \n                           Sildenafil\n    \n     bwhen dosed as REVATIO\n    \n     ®for the treatment of pulmonary arterial hypertension \n     \n                           \n                        \n                        \n                           Protease Inhibitors  \n     \n                           \n                           Indinavir \n     \n                           \n                        \n                        \n                           Non-nucleoside Reverse Transcriptase Inhibitors \n     \n                           \n                           Nevirapine \n     \n                           \n                        \n                     \n                  \n                  \n                     a See\n \n  Drug Interactions, Table 16 (\n  \n   7)\n \n  for parenterally administered midazolam. \n  \n                     b  See\n \n  Drug Interactions, Table 16 (\n  \n   7)\n \n  for sildenafil when dosed as VIAGRA\n \n  ®for erectile dysfunction."
}